Dynavax Technologies Corp DVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DVAX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $11.84
- Day Range
- $11.70–12.08
- 52-Week Range
- $10.06–15.15
- Bid/Ask
- $11.34 / $11.99
- Market Cap
- $1.54 Bil
- Volume/Avg
- 1.1 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 19.06
- Price/Sales
- 6.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 408
- Website
- https://www.dynavax.com
Comparables
Valuation
|
Metric
|
DVAX
|
NWBO
|
VIR
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.06 | — | — |
Price/Book Value | 2.47 | — | 0.71 |
Price/Sales | 6.56 | 292.87 | 28.39 |
Price/Cash Flow | 38.73 | — | — |
Price/Earnings
DVAX
NWBO
VIR
Financial Strength
|
Metric
|
DVAX
|
NWBO
|
VIR
|
|---|---|---|---|
Quick Ratio | 12.65 | 0.05 | 8.68 |
Current Ratio | 13.81 | 0.09 | 9.05 |
Interest Coverage | −4.38 | −10.94 | — |
Quick Ratio
DVAX
NWBO
VIR
Profitability
|
Metric
|
DVAX
|
NWBO
|
VIR
|
|---|---|---|---|
Return on Assets (Normalized) | 3.72% | −179.00% | −20.03% |
Return on Equity (Normalized) | 6.14% | — | −25.63% |
Return on Invested Capital (Normalized) | 1.92% | — | −28.31% |
Return on Assets
DVAX
NWBO
VIR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Dhsjcrkcl | Czsm | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Hxcmtzgmg | Wpgknj | $68.4 Bil | |
HLN
| Haleon PLC ADR | Ybvkvyxrq | Vjxw | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Mjdwfvhbh | Pwj | $14.5 Bil | |
VTRS
| Viatris Inc | Dkyklhqn | Rrt | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Rhcmvfrgn | Ynkxv | $12.0 Bil | |
CTLT
| Catalent Inc | Tsgxrvx | Lxwlw | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Kydvstcl | Pcgg | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Jcqfnbzm | Mnm | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Cgsqxpcq | Lnkmpky | $3.5 Bil |